This article is more than 5 years old. Information may no longer be current.

Alimera sees second quarter revenue increase

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alimera Sciences had an increase in consolidated net revenue of 8% to $10.4 million in the second quarter of 2017 compared with $9.6 million in the second quarter of 2016.

U.S. revenue increased from $7.2 million to $8.1 million, driven by higher sales of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg), while international revenue remained flat at $2.3 million, according to a company press release.

Quarterly GAAP net loss was $2.8 million, or $0.04 per share, compared with a net loss of $6.9 million, or $0.15 per share, in 2016’s third quarter.

Operating expenses decreased from $15.5 million in the second quarter of 2016 to $11 million in the second quarter of 2017.